Spinal motion and secondary injury prevention
›Secondary injury mitigation bundle
›Spinal motion restriction maintained until clearance
›Neutral alignment
›Log-roll technique for turns
›Oxygenation
›SpO2 at least 94%
›Avoid hypercapnia
›Perfusion
›Avoid hypotension
›MAP augmentation plan
›Neurogenic shock management
›Initial approach
›Crystalloid bolus if hypovolemia possible
›Reassess perfusion response
›Early vasopressor if persistent hypotension with bradycardia pattern
›Neurogenic shock physiology
›MAP augmentation targets
›MAP at least 75 to 80 mmHg
›Weak recommendation
›Very low quality evidence
›AO Spine and Praxis 2024 hemodynamic guideline
›MAP not higher than 90 to 95 mmHg
›Weak recommendation
›Very low quality evidence
›AO Spine and Praxis 2024 hemodynamic guideline
›Vasopressor selection
›Norepinephrine preferred for mixed vasoplegia and relative bradycardia pattern
›If persistent hypotension, start norepinephrine infusion
›Initial 0.05 micrograms per kg per minute
›Titrate every 2 to 5 minutes
›Usual range 0.05 to 1 microgram per kg per minute
›If severe vasoplegia, higher doses per institutional protocol
›Central line consideration
›Phenylephrine for pure vasoplegia with preserved heart rate
›If tachyarrhythmia limits norepinephrine, switch to phenylephrine
›Initial 0.2 micrograms per kg per minute
›Titrate every 2 to 5 minutes
›Usual range 0.2 to 3 micrograms per kg per minute
›Epinephrine for refractory shock with myocardial dysfunction
›If shock refractory, epinephrine infusion
›Initial 0.02 micrograms per kg per minute
›Titrate every 2 to 5 minutes
›Usual range 0.02 to 0.5 micrograms per kg per minute
›Bradycardia treatment
›Atropine for symptomatic bradycardia
›If symptomatic bradycardia, atropine 0.5 mg IV
›Repeat every 3 to 5 minutes
›Maximum 3 mg IV
›Transcutaneous pacing for refractory instability
›If unstable bradycardia refractory, initiate pacing
›Monitoring
›Arterial line for frequent MAP titration
›Continuous ECG monitoring
›Urine output trend
›Ventilatory support for high cervical injury
›Intubation strategy
›Video laryngoscopy with in-line stabilization if available
›Avoid excessive neck movement
›Ventilation targets
›Normocapnia
›Avoid atelectasis with adequate PEEP
›Anticipatory transfer airway
›If marginal ventilation and long transfer, intubate before transport
Decompression and stabilization
›Surgical management pathway
›Early surgery window
›Recommended surgery within 24 hours when medically feasible
›Acute SCI guideline update 2024
›Decompression prior to 24 hours associated with improved neurologic outcome in STASCIS study
›Indications
›Ongoing cord compression
›Progressive neurologic deficit
›Unstable fracture or dislocation
›Epidural hematoma with deficit
›Preoperative imaging
›MRI prior to surgery when feasible
›Weak recommendation
›Very low quality evidence
›AO Spine 2017 MRI guideline
›Steroids
›Methylprednisolone high-dose
›Not a treatment standard or guideline
›CAEP position statement
›Insufficient evidence for routine use
›Treatment option within 8 hours in some guidelines
›Weak recommendation
›Moderate quality evidence
›AO Spine 2017 guideline
›Adverse effects risk
›Infection risk
›GI bleeding risk
›Hyperglycemia risk
›Analgesia and sedation
›Multimodal pain control
›Acetaminophen 1 g PO or IV every 6 hours
›Maximum 4 g per day
›Ibuprofen 400 mg PO every 6 hours if no contraindication
›Renal and bleeding risk screening
›Opioid for severe pain
›Morphine 0.05 mg per kg IV
›Repeat every 10 minutes as needed
›Hydromorphone 0.01 mg per kg IV
›Repeat every 10 minutes as needed
›Venous thromboembolism prophylaxis
›Mechanical prophylaxis
›Intermittent pneumatic compression unless contraindicated
›Pharmacologic prophylaxis when bleeding risk acceptable
›Enoxaparin 30 mg subcutaneous every 12 hours
›Renal adjustment if low creatinine clearance
›Coordination with surgical timing
›Unfractionated heparin alternative
›5000 units subcutaneous every 8 hours
›Bladder management
›Urinary retention management
›Indwelling catheter for acute retention
›Strict urine output tracking
›Bowel regimen
›Constipation prevention
›Polyethylene glycol 17 g PO daily
›Senna 8.6 mg PO at bedtime
›Temperature management
›Normothermia target
›Fever worsens secondary injury risk
›Pressure injury prevention
›Turning schedule
›Pressure-relieving surfaces